Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.09.09
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submissio ...
PDF (261 KB)
2019.08.21
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and ...
PDF (297 KB)
2019.11.04
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugat ...
PDF (132 KB)
2019.04.09
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Tre ...
PDF (186 KB)
2019.04.04
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with ...
PDF (168 KB)
2019.04.29
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam ...
PDF (218 KB)
2019.05.31
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EG ...
PDF (158 KB)
2019.05.14
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 I ...
PDF (266 KB)
2020.01.06
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...
PDF (253 KB)
2019.11.19
Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with ...
PDF (181 KB)
Showing 1 - 10 of 34 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...